FAQ on Soligenix Inc.'s Phase 2a SGX945 Study for Behçet’s Disease
Summary
Soligenix Inc. has successfully demonstrated biological efficacy in its Phase 2a study of SGX945 for Behçet’s Disease, showing significant improvement in ulcer outcomes compared to a historical placebo group, with plans to advance the treatment for broader use.
What is SGX945 and what disease does it target?
SGX945 (dusquetide) is a treatment developed by Soligenix Inc. targeting Behçet’s Disease, a rare inflammatory condition, as part of its innate defense regulator (IDR) technology portfolio.
What were the key findings of the Phase 2a study?
The study showed a 40% improvement in the primary ulcer endpoint compared to a historical placebo group, with seven of eight patients reporting reduced ulcer duration, number, and pain, and no treatment-related adverse events.
How does SGX945 compare to apremilast (Otezla(R))?
SGX945 matched or exceeded the outcomes of apremilast in the Phase 3 study, despite treatment stopping at four weeks, indicating its potential as an effective alternative.
What are the next steps for SGX945?
Soligenix plans to advance SGX945, including reformulating it for home-based subcutaneous administration, to address unmet needs in Behçet’s Disease and other inflammatory conditions.
Who is leading Soligenix Inc.?
Christopher J. Schaber is the CEO of Soligenix Inc., overseeing the company’s efforts in developing treatments for rare diseases with unmet medical needs.
Where can I find more information about Soligenix and its studies?
More information is available on Soligenix’s website at www.Soligenix.com and in the company’s newsroom at https://ibn.fm/SNGX.
What other treatments is Soligenix developing?
Soligenix is developing HyBryte(TM) for cutaneous T-cell lymphoma, SGX942 for inflammatory diseases, and vaccine programs including RiVax(R) for ricin toxin and CiVax(TM) for COVID-19, among others.
How is Soligenix’s Public Health Solutions business segment funded?
This segment is supported by government grants and contracts from the NIAID, DTRA, and BARDA, focusing on vaccine development for threats like ricin toxin, filoviruses, and SARS-CoV-2.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 129175